# Immix Biopharma

Source: https://onco.cc/companies/immix-biopharma/  
OnCo record `immix-biopharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Immix Biopharma is a Los Angeles cell-therapy company whose BCMA CAR-T NXC-201 is the first CAR-T to show deep responses in AL amyloidosis, the disease in which misfolded antibody fragments damage the heart and kidneys.

## Summary

Immix Biopharma, through its subsidiary Nexcella, develops NXC-201 (formerly HBI0101), a BCMA-directed CAR-T cell therapy originally created at Hadassah Medical Center in Jerusalem. NXC-201 is being studied in the NEXICART-2 trial in relapsed or refractory AL amyloidosis, where it holds orphan and regenerative medicine advanced therapy designations, and in multiple myeloma. The company also has the tissue-specific therapeutic IMX-110 for soft tissue sarcoma.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Immix Biopharma, Inc.; Nexcella; NASDAQ:IMMX
- Tags: drug-maker
- HQ: Los Angeles, California
- Type: cell-therapy
- Website: https://www.immixbio.com/
- Ticker: NASDAQ:IMMX

## Sources

- Official website: https://www.immixbio.com/

## Connected records

- drugs: [NXC-201 CAR-T](https://onco.cc/drugs/nxc-201-car-t/)

---
JSON: https://onco.cc/api/v1/entities/immix-biopharma.json